5 Key Takeaways

• 1

  The PRIMAvera trial demonstrated that a subretinal photovoltaic implant restored central vision in patients with advanced geographic atrophy.

• 2

  At 12 months, 26 of 32 evaluable participants achieved a clinically meaningful improvement in visual acuity with the PRIMA system.

• 3

  The PRIMA system includes a subretinal implant, a pocket processor, and glasses that project near-infrared light for vision restoration.

• 4

  Eighty-four percent of participants reported the ability to read letters or words at home using the PRIMA device.

• 5

  The study found that the benefits of the PRIMA implant outweighed the procedural risks, with most adverse events being mild or moderate.